Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
New Alzheimer’s launches are all but ruled out, so projects from Lilly, Alynlam and Roche top 2022’s biggest hopes.